Profile data is unavailable for this security.
About the company
Oncopeptides AB is a Sweden-based biotech company focused on the development of targeted therapies for difficult-to-treat hematological diseases. The Company’s lead product candidate PEPAXTO (melphalan flufenamide, also known as melflufen) has been approved in relapsed or refractory multiple myeloma by The U.S. Food and Drug Administration. Melphalan flufenamide is the first drug originated from the Company PDC-platform and is evaluated in a clinical study program, including the ongoing phase 3 OCEAN study. Melphalan flufenamide is an anticancer peptide-drug conjugate for patients with relapsed or refractory multiple myeloma. The drug uses technology that links a peptide carrier to a cytotoxic agent, resulting in a lipophilic compound. Due to its high lipophilicity, it is distributed into the cells. Melphalan flufenamide is designed to leverage aminopeptidases, enzymes which are overexpressed in myeloma cells and cause the release of the cytotoxic agents in the cells.
- Revenue in SEK (TTM)39.17m
- Net income in SEK-245.79m
- Incorporated2000
- Employees62.00
- LocationOncopeptides ABLuntmakargatan 46, 7th floorSTOCKHOLM 111 37SwedenSWE
- Phone+46 86152040
- Websitehttps://www.oncopeptides.se/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lifecare ASA | 12.84m | -34.58m | 337.12m | 32.00 | -- | 4.23 | -- | 26.26 | -0.2454 | -0.2454 | 0.092 | 0.4163 | 0.1621 | -- | 4.90 | 408,943.10 | -43.60 | -40.00 | -49.97 | -45.26 | -- | -- | -269.03 | -175.53 | -- | -- | 0.1812 | -- | -40.88 | 30.29 | -101.74 | -- | -- | -- |
| Curasight A/S | -44.76m | -46.14m | 344.17m | 4.00 | -- | 9.36 | -- | -- | -1.47 | -1.47 | -1.43 | 1.18 | -0.6914 | -- | -- | -7,114,500.00 | -71.27 | -24.61 | -77.08 | -26.01 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -123.97 | -- | -42.62 | -- | -- | -- |
| Guard Therapeutics Intrntnl AB (publ) | 0.00 | -87.91m | 349.62m | 6.00 | -- | 5.50 | -- | -- | -8.74 | -8.74 | 0.00 | 5.27 | 0.00 | -- | -- | -- | -75.10 | -69.56 | -91.32 | -78.62 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.4289 | -- | -- | -- |
| SynAct Pharma AB | 0.00 | -190.84m | 350.61m | 5.00 | -- | 1.98 | -- | -- | -5.65 | -5.65 | 0.00 | 4.28 | 0.00 | -- | -- | 0.00 | -71.43 | -125.17 | -79.52 | -151.70 | -- | -- | -- | -- | -- | -853.13 | 0.0033 | -- | -- | -- | -117.54 | -- | -- | -- |
| Herantis Pharma Oyj | 0.00 | 3.29m | 363.32m | 10.00 | 122.12 | 6.55 | 110.59 | -- | 0.0126 | 0.0126 | 0.00 | 0.2344 | 0.00 | -- | -- | 0.00 | 4.31 | -80.46 | 6.16 | -104.37 | -- | -- | -- | -- | -- | -- | 0.0073 | -- | -- | -- | 103.00 | -- | -- | -- |
| Xbrane Biopharma AB | 190.97m | -361.27m | 389.25m | 75.00 | -- | 0.9877 | -- | 2.04 | -1.33 | -1.58 | 0.6978 | 0.2577 | 0.2465 | 1.34 | 332.12 | 2,053,430.00 | -46.63 | -40.98 | -78.01 | -67.24 | 15.43 | -- | -189.18 | -364.40 | 1.43 | -31.13 | 0.3693 | -- | 314.33 | 63.42 | -91.10 | -- | 60.02 | -- |
| Annexin Pharmaceuticals AB (publ) | 0.00 | -52.36m | 409.33m | 4.00 | -- | 11.36 | -- | -- | -0.1873 | -0.1873 | 0.00 | 0.0676 | 0.00 | -- | -- | 0.00 | -162.59 | -125.42 | -220.41 | -151.33 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -8.17 | -- | -- | -- |
| Mendus AB (publ) | 0.00 | -107.06m | 410.43m | 28.00 | -- | 0.5233 | -- | -- | -1.59 | -1.59 | 0.00 | 15.57 | 0.00 | -- | -- | 0.00 | -16.09 | -18.84 | -17.35 | -20.21 | -- | -- | -- | -28,474.53 | -- | -150.86 | 0.0348 | -- | -100.00 | -- | 26.78 | -- | -- | -- |
| Lytix Biopharma AS | 3.91m | -86.21m | 437.94m | 10.00 | -- | 7.13 | -- | 111.87 | -2.16 | -2.16 | 0.0981 | 1.26 | 0.0368 | -- | 0.4091 | 399,100.00 | -80.96 | -56.91 | -94.07 | -65.83 | -- | -- | -2,202.36 | -771.78 | -- | -- | 0.0095 | -- | -63.82 | 63.94 | -56.77 | -- | -- | -- |
| Initiator Pharma A/S | 0.00 | -35.49m | 460.26m | 3.00 | -- | 13.08 | -- | -- | -0.6518 | -0.6518 | 0.00 | 0.6651 | 0.00 | -- | -- | 0.00 | -70.60 | -68.27 | -73.77 | -74.02 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 27.95 | -- | -- | -- |
| Saniona AB | 20.71m | -83.30m | 489.45m | 23.00 | -- | 17.95 | -- | 23.63 | -1.09 | -1.09 | 0.2629 | 0.2451 | 0.1726 | -- | 5.63 | 900,521.80 | -69.41 | -59.16 | -127.89 | -70.15 | -136.88 | -970.05 | -402.20 | -1,483.55 | -- | -3.85 | 0.71 | -- | 10.19 | -21.05 | 54.71 | -- | -34.94 | -- |
| Hamlet BioPharma AB | 0.00 | -33.41m | 498.28m | 7.00 | -- | 8.61 | -- | -- | -0.2326 | -0.2326 | 0.00 | 0.453 | 0.00 | -- | -- | -- | -63.45 | -83.52 | -69.09 | -107.84 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -18.87 | -- | 78.01 | -- |
| Bergenbio ASA | 511.02k | -151.56m | 508.75m | 16.00 | -- | 382.33 | -- | 995.56 | -0.1849 | -0.1849 | 0.0003 | 0.0347 | 0.0047 | -- | 0.0485 | 20,840.00 | -139.81 | -66.15 | -275.19 | -78.74 | -- | -- | -29,658.54 | -11,419.44 | -- | -- | 0.00 | -- | -9.00 | -31.43 | 36.98 | -- | -- | -- |
| Oncopeptides AB | 39.17m | -245.79m | 525.45m | 62.00 | -- | -- | -- | 13.42 | -1.93 | -1.93 | 0.3085 | -0.0664 | 0.1517 | -0.2669 | 0.8075 | 687,157.90 | -95.16 | -141.28 | -135.11 | -200.49 | 102.05 | -- | -627.53 | -2,689.06 | 2.33 | -- | 1.06 | -- | 321.54 | -- | 26.29 | -- | -- | -- |
| Promimic AB | 39.53m | -9.38m | 662.34m | 17.00 | -- | 9.07 | -- | 16.75 | -0.5067 | -0.5067 | 2.14 | 3.91 | 0.4533 | -4.61 | 5.46 | 2,325,471.00 | -10.75 | -24.89 | -12.43 | -29.25 | 104.25 | 101.23 | -23.73 | -89.47 | 4.13 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Cantargia AB | 0.00 | -241.07m | 696.17m | 23.00 | -- | 5.24 | -- | -- | -1.40 | -1.40 | 0.00 | 0.7239 | 0.00 | -- | -- | 0.00 | -83.14 | -55.08 | -107.52 | -61.35 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 24.69 | -- | -- | -- |
Data as of Jul 29 2024. Currency figures normalised to Oncopeptides AB's reporting currency: Swedish Krona SEK
10.38%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Redmile Group LLCas of 31 May 2024 | 13.95m | 6.61% |
| Handelsbanken Fonder ABas of 30 Jun 2024 | 5.30m | 2.51% |
| SEB Investment Management ABas of 28 Jun 2024 | 1.14m | 0.54% |
| FCG Fonder ABas of 30 Jun 2024 | 763.01k | 0.36% |
| Storebrand Asset Management ASas of 30 Jun 2024 | 526.82k | 0.25% |
| Skandia Investment Management ABas of 31 May 2024 | 140.23k | 0.07% |
| Lancelot Asset Management ABas of 30 Jun 2020 | 56.13k | 0.03% |
| Fund Development & Advisory AGas of 31 Dec 2023 | 11.93k | 0.01% |
| DFP Deutsche Finanz Portfolioverwaltung GmbHas of 31 Dec 2023 | 5.61k | 0.00% |
| Danske Bank A/S (Investment Management)as of 30 Jun 2024 | 4.33k | 0.00% |
More ▼
Data from 30 Jun 2023 - 30 Jun 2024Source: FactSet Research Systems Inc.
